Recommendations for the use of slow-release oral morphine as opioid agonist therapy
Evidence, Guidelines and Recommendations
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).
Amidst a provincial overdose crisis, British Columbia made concerted efforts to address gaps in the provision of evidence-based treatment options and care for individuals with opioid use disorder, including the development of provincial guidelines as well as the creation of its aligned training program, the Provincial Opioid Addiction Treatment Support Program.
Amidst a provincial overdose crisis, British Columbia made concerted efforts to address gaps in the provision of evidence-based treatment options and care for individuals with opioid use disorder, including the development of provincial guidelines as well as the creation of its aligned training program, the Provincial Opioid Addiction Treatment Support Program.
This guideline was developed to provide Canadian health professionals with an educational tool and clinical practice recommendations for the treatment of opioid use disorder.
This guideline was developed to provide Canadian health professionals with an educational tool and clinical practice recommendations for the treatment of opioid use disorder.
Find 15 specialty-specific recommendations for when the use of opioids should not be first line therapy and information resources to help patients have informed conversations with their clinicians about safe options for managing pain.
Find 15 specialty-specific recommendations for when the use of opioids should not be first line therapy and information resources to help patients have informed conversations with their clinicians about safe options for managing pain.
